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A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as ﬁrst-line
chemotherapy in patients with urothelial cancer. Thirty-eight patients with locally advanced or metastatic transitional-cell
carcinoma of the bladder, renal pelvis or ureter received the combination of docetaxel 75 mg m
72 and cisplatin 75 mg m
72
on day 1 and repeated every 21 days, to a maximum of six cycles. The median delivered dose-intensity was 98% (range 79–
102%) of the planned dose for both drugs. There were seven complete responses and 15 partial responses, for and overall
response rate of 58% (95% CI, 41–74%). Responses were even seen in three patients with hepatic metastases. The median
time to progression was 6.9 months, and the median overall survival was 10.4 months. Two patients who achieved CR status
remain free of disease at 4 and 3 years respectively. Grade 3–4 granulocytopenia occurred in 27 patients, resulting in ﬁve
episodes of febrile neutropenia. There was one toxic death in a patient with grade 4 granulocytopenia who developed acute
abdomen. Grade 3–4 thrombocytopenia was rare (one patient). Other grade 3–4 toxicities observed were anaemia (three
patients), vomiting (ﬁve patients), diarrhoea (four patients), peripheral neuropathy (two patients) and non-neutropenic
infections (seven patients). Docetaxel plus cisplatin is an effective and well-tolerated regimen for the treatment of advanced
urothelial cancer, and warrants further investigation.
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Chemotherapy is the treatment of choice for patients with locally
advanced and metastatic urothelial cancer. The combination of
methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC)
has been the most widely used regimen, with reported response
rates of 36 and 78% (Sternberg et al, 1989; Saxman et al, 1997).
Long-term results of the Phase III Intergroup Study showed that
the treatment with M-VAC provided a signiﬁcant survival advan-
tage over cisplatin alone (Saxman et al, 1997). Moreover, after a
major response to chemotherapy, a small number of patients
(4.3%) remained free of disease after long-term follow-up. This
percentage of long-term survivors may be increased when postche-
motherapy surgery or radiotherapy is performed in selected
responding patients (Fossa et al, 1996; Dodd et al, 1999). The data
showed that urothelial cancer is a disease sensitive to chemother-
apy. However, its long-term results are still poor and its toxicity
is substantial. Therefore, in recent years the necessity arose to iden-
tify new drugs and schedules that were more active and tolerable
than the ones that were currently being used.
Docetaxel is a wide spectrum chemotherapeutic agent that acts
by promoting and stabilizing the assembly of microtubules, result-
ing in the inhibition of cellular division. In phase II trials, it has
shown activity against advanced bladder carcinoma (McCaffrey et
al, 1997; de Wit et al, 1998). Cisplatin has been considered the
principal agent in the treatment of urothelial cancer. The objective
of this study is to evaluate the activity and toxicity of the combina-
tion of docetaxel and cisplatin in ﬁrst-line treatment of advanced
urothelial cancer.
MATERIALS AND METHODS
Patients
Patients with histological conﬁrmation of metastatic or locally
advanced (T4b, N2-3) transitional-cell carcinoma of the bladder,
renal pelvis or ureter, not curable with surgery, were eligible.
Patients with mixed tumours including transitional-cell carcinoma
were considered eligible, whereas those with pure squamous,
adenocarcinoma, or small-cell carcinoma were not. Patients must
not have received prior chemotherapy for advanced disease,
although prior adjuvant or neoadjuvant chemotherapy was allowed
if this was completed more than 6 months before study entry.
Patients were required to have bidimensional measurable disease
and no previous radiotherapy of the indicator lesion. Patients were
also required to be 18 years or older, with a Karnofsky perfor-
mance status of 60 to 100. Other inclusion criteria were as
C
l
i
n
i
c
a
l
Received 3 August 2001; revised 13 November 2001; accepted
5 December 2001
*Correspondence: X Garcia del Muro; E-mail: garciadelmuro@csub.scs.es
British Journal of Cancer (2002) 86, 326–330
ã 2002 The Cancer Research Campaign All rights reserved 0007–0920/02 $25.00
www.bjcancer.comfollows: normal baseline haematologic parameters, creatinine clear-
ance of 60 ml min
71 or more, a normal bilirubin level, a alkaline
phosphatase level of less than six times the upper normal limit, and
transaminase levels of less than 3.5 times the upper normal limit or
less than 1.5 times in case of association with alkaline phosphatase
greater than 2.5 times the norm. Patients with known CNS metas-
tases, pre-existing grade 1 peripheral neuropathy, history of prior
malignancy, or signiﬁcant cardiac disease were not eligible for this
study. Written informed consent was obtained from all patients
before study entry. The study was carried out with ethical commit-
tee approval at each participating hospital.
Treatment schedule
Docetaxel was administered at a dose of 75 mg m
72, diluted in
250 ml of 5% glucose, as a 1 h infusion. Cisplatin 75 mg m
72
was infused in 500 ml of normal saline over 30–60 min, with
adequate pre- and post-hydration and mannitol. Both drugs were
given on day 1 and repeated every 3 weeks. Premedication included
dexamethasone, 8 mg orally b.i.d., the day before and four conse-
cutive days following chemotherapy. Antiemetic treatment
consisted of intravenous ondansetron or granisetron in combina-
tion with dexamethasone 20 mg on day 1. Cycles were not
started unless the granulocyte count was 41500 mm
73 and plate-
lets were 4100000 ml
71. Prophylactic use of growth factors (G-
CSF) was not routinely recommended. However, if grade 4 granu-
locytopenia or febrile neutropenia was present, prophylactic
Lenograstim, 263 mg day
71 over 10 days, was administered in
subsequent cycles. The docetaxel dose was reduced to
55 mg m
72 if patients experienced grade 4 thrombocytopenia,
febrile neutropenia despite prophylactic administration of G-CSF,
or grade 2 hepatotoxicity. Doses of both agents were reduced by
25% if patients experienced grade 2 peripheral neuropathy. Patients
were taken off the study if creatinine clearance decreased to less
than 50 ml min
71. Patients received treatment for a maximum
of six cycles unless they developed progressive disease or experi-
enced excessive toxicity as judged by the investigator or the patient.
Outcome evaluation
National Cancer Institute common toxicity criteria were used to
analyze toxicity. Response evaluation was performed every three
cycles using standard WHO criteria. Even patients receiving just
one course were considered evaluable for response and toxicity
assessment. Patients were followed for survival and disease progres-
sion every 3 months until death or loss to follow-up. The method
of Kaplan–Meier was used to estimate duration of response, time
to progressive disease and overall survival. The planned sample size
was 35 patients, using a two-stage sequential design, with the
assumption that the regimen would not be of interest if it had a
response rate of less than 30% but would be of considerable inter-
est if it had a response proportion of 50% or more (Fleming,
1982).
RESULTS
From February 1997 to August 1999, 38 patients were entered into
the study at seven centres. All patients were eligible for the study,
and all assessable for toxicity and response. Pre-treatment charac-
teristics of the patients are summarized in Table 1. Twenty
(53%) patients had locally advanced or metastatic lymph node
disease, and the remaining 18 (47%) had metastatic visceral or soft
tissue disease. Six patients had received prior systemic adjuvant
chemotherapy with cisplatin or carboplatin-containing regimens.
A total of 166 cycles of chemotherapy were administered. The
median number of cycles received per patient was six (range, 1–
6 completed cycles). Of the 38 patients, 35 (92%) received at least
two cycles of chemotherapy. The median delivered dose-intensity
was 98% (range, 79–102%) of the planned dose for both drugs.
Fifteen patients received G-CSF in a total of 48 cycles of
chemotherapy. G-CSF was administered prophylactically in 42
cycles, and as a treatment of febrile neutropenia in six cycles. Over-
all, patients were ultimately withdrawn from therapy due to
progressive disease (nine patients), adverse events (six patients),
stable disease (three patients), or request (one patient). Twenty-
two of the 38 assessable patients obtained an objective response,
for an overall response rate of 58% (95% conﬁdence interval
(CI), 41–74%), with seven patients obtaining a radiological
complete response (CR, 18%) and 15 a partial response (PR,
39.5%). An additional four patients (10.5%) had stable disease,
and 11 patients had progressive disease. Responses were seen in
three out of the six patients who had received prior adjuvant
chemotherapy. Fifteen of the 22 patients who achieved a response
had locally advanced or metastatic lymph node disease exclusively.
However, ﬁve patients had visceral metastases, including three with
liver and two with lung disease, and two additional patients had
soft tissue metastases. The median duration of response was 10.5
months (95% CI, 7.6 to 16.8). The median time to progressive
disease was 6.9 months (95% CI, 6.2 to 10.5), and the median
overall survival time for all patients was 10.4 months (95% CI,
6.3 to 17.4 months). At the time of the report, two patients who
had achieved CR status remain alive and free of recurrence at 48
and 36 months respectively. Both had exclusively locally advanced
and lymph node disease before the chemotherapy. One of them
underwent salvage cystectomy after chemotherapy, and no viable
tumour was found at pathological study.
Table 2 lists the maximum grade of common toxicities observed
in each patient. Grade 3 and 4 toxicities were primarily haemato-
logical. Twenty-seven (71%) patients experienced grade 3 or 4
granulocytopenia; however, only ﬁve (13%) patients in ﬁve of
the total cycles experienced febrile neutropenia. Three patients
developed grade 3 anaemia. Clinically signiﬁcant thrombocytopenia
was observed in one patient. There was one toxic death in a patient
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Table 1 Baseline patient characteristics
Characteristic Number of patients (n=38)
Age, years
Median 62
Range 43–72
Sex
Male 36
Female 2
Performance status (Karnofsky index)
100% 7
90% 10
80% 14
70% 7
Primary tumour site
Bladder 33
Upper tract 5
Prior chemotherapy
Adjuvant 6
None 32
Sites of disease
Lymph nodes/local disease only 20
Visceral metastases (dominant site) 18
Lung and pleura 4
Liver 8
Bone 4
Soft tissue 2
Number of sites of disease
12 1
21 5
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Grade 3 and 4 nonhaematologic toxicity was experienced by ﬁve
(13%) patients with nausea and vomiting, four patients (10%) with
diarrhoea, two patients (5%) with peripheral neuropathy, and one
patient with renal toxicity. A total of seven patients had severe
non-neutropenic infections, that consisted of four urinary tract
infections, two pneumonia, and one candida lung abscess in a
patient with concurrent corticoesteroid treatment. One patient died
on study due to gastrointestinal haemorrhage without thrombocy-
topenia. Two patients experienced episodes of cardiac arrhythmias,
and one patient had a myocardial infarction. Most patients had
some degree of fatigue with this therapy that did not lead to dose
modiﬁcation. Hair loss was common and 27 (71%) patients had
total alopecia. Infusion-related hypersensitivity reactions were seen
in ﬁve patients and all were mild (grade 1 and 2). Severe bronch-
ospasm was not observed. Grade 1 and 2 ﬂuid retention occurred
in ﬁve and two patients respectively, and it was generally noted
after four or ﬁve cycles of treatment.
DISCUSSION
The initial experience with docetaxel in the treatment of urothelial
cancer demonstrated single-agent activity in a series of patients
previously treated with chemotherapy (McCaffrey et al, 1997).
One trial performed on 30 chemotherapy-naive patients showed
a response rate of 31% (de Wit et al, 1998), suggesting that doce-
taxel could be among the drugs with high activity against urothelial
cancer. In addition, docetaxel can be administered safely to patients
with impaired renal function (Dimopoulos et al, 1998), a condition
frequently associated with bladder carcinoma.
The present study evaluated docetaxel in combination with
cisplatin which is generally considered to be the most active agent
against urothelial cancer. Prior phase I studies showed the feasibil-
ity of this combination and its activity on different tumours (Pronk
et al, 1997). The response rate observed for urothelial cancer in our
study is within the range of the responses seen with other conven-
tional (Sternberg et al, 1989) and newer schedules (Von der Maase
et al, 1999; Dreicer et al, 2000) which are considered highly active.
Responses were even seen in patients with visceral metastases,
traditionally considered resistant to M-VAC chemotherapy, and
also in patients previously treated with adjuvant chemotherapy,
where the proportion of responses was similar to the whole group.
It should be noted that two patients in our series have achieved
long-term survival. At the time of the report, they remained alive
and free of disease, at 4 and 3 years from the treatment.
The toxicity of this regimen was generally acceptable and
manageable. The most common toxicity was haematological, mainly
granulocytopenia. However, most episodes of granulocytopenia
were brief and did not cause clinical repercussion, since only 13%
of the patients experienced febrile neutropenia. Nevertheless, there
was a toxic death associated with acute abdomen and severe granu-
locytopenia. This rare and serious complication has been reportedly
associated with different chemotherapy schedules, including doce-
taxel (Cardenal et al, 1996). Also, several episodes of serious non-
neutropenic infections were observed. They were probably linked
to comorbidities and complications due to the neoplasm rather than
to the treatment itself. In spite of the potential neurotoxicity of
cisplatin and docetaxel, there was not a signiﬁcantly high incidence
of severe peripheral neuropathy. The incidence of thrombocytopenia
and mucositis, two complications that may cause important
morbidity and are frequently seen with other common regimens
(Von der Maase et al, 2000), was very low.
Recently, two studies that used the same regimen in bladder
carcinoma have been reported (Sengelov et al, 1998; Dimopoulos
et al, 1999) (Table 3). The results of these three studies conﬁrm
the efﬁcacy of this regimen. Variations in the distribution of pre-
treatment prognostic features and the multicentre nature of two
studies could justify the differences in the results between them.
The toxicity proﬁle observed was similar in the three studies, the
side effects being generally of mild to moderate intensity.
Two additional studies have evaluated docetaxel in other combi-
nations in the treatment of urothelial cancer. One of them
evaluated the three-drug combination with cisplatin and epirubicin
(Pectasides et al, 2000). The response rate was 66.7% and the
median overall survival was 14.5 months. Nevertheless, more than
half of the patients required dose reductions due to haematological
toxicity, despite the frequent use of G-CSF. The other study
assessed the association of docetaxel and ifosfamide after failure
of cisplatin-based chemotherapy (Krege et al, 2001). This combina-
tion showed activity with acceptable tolerability.
In the last few years, several clinical trials aimed at identifying
polychemotherapy regimens with new drugs active against urothe-
lial cancer have been initiated. The objective has been to ﬁnd
combinations that demonstrate improved efﬁcacy and a better toxi-
city proﬁle compared with that of M-VAC. The most extensively
studied drugs have been gemcitabine (Moore et al, 1999; Von
der Maase et al, 1999; Kaufman et al, 2000) and paclitaxel
(Redman et al, 1998; Vaughn et al, 1998; Zielinski et al, 1998; Drei-
cer et al, 2000; Small et al, 2000), each in combination with
cisplatin or carboplatin. These studies have usually shown an
elevated activity with a favourable toxicity proﬁle (Table 3).
However, comparing results of different phase II trials is unreliable,
because they are very dependent on the prognostic features of the
patients included in the trials (Bajorin et al, 1999). At the moment,
there is only one phase III trial available comparing gemcitabine
plus cisplatin to standard M-VAC (von der Maase et al, 2000).
Four hundred and ﬁve patients were included, and no differences
in activity in both regimens were found. However, the tolerance
proﬁles were different, showing a signiﬁcantly lower incidence of
serious granulocytopenia and mucositis in the patients treated with
gemcitabine plus cisplatin.
A few trials with three-drug regimens containing two new drugs
have also been performed in recent years. The combination of
paclitaxel, gemcitabine and cisplatin (Bellmunt et al, 2000); the
one with ifosfamide, paclitaxel and cisplatin (Bajorin et al, 1998);
and one with paclitaxel, gemcitabine and carboplatin (Hussain et
al, 2001) showed promising activity with predominantly haemato-
logical toxicity. The last study was comprised of patients with
normal and poor renal function (Hussain et al, 2001). The associa-
tion of paclitaxel, vinblastine and cisplatin, however, resulted in a
poor efﬁcacy (Mulatero et al, 2000). Another new approach
studied, with preliminary encouraging results, consisted of a
sequential schedule with doxorubicin and gemcitabine followed
by ifosfamide, paclitaxel and cisplatin (Dodd et al, 2000).
In summary, the present study shows that the association of
docetaxel and cisplatin is an effective regimen in the treatment
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Table 2 Worst toxicity by patient
Grade
Toxicity 1 2 3 4
Granulocytopenia 2 5 12 15
Thrombocytopenia 3 1 – –
Anaemia 15 10 3 –
Vomiting 6 12 5 –
Mucositis 8 2 – –
Diarrhoea 4 10 3 1
Fatigue 6 14 13 –
Alopecia 5 25 2 –
Peripheral neuropathy 15 1 2 –
Hypersensitivity reaction 2 3 – –
Fluid retention 5 2 – –
Skin changes 6 1 – –
Nephrotoxicity 3 2 – –
Infection 5 6 4 3
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British Journal of Cancer (2002) 86(3), 326–330 ã 2002 The Cancer Research Campaignof advanced urothelial cancer. The results also show that a small
number of patients, who would otherwise succumb to disease,
can achieve long-term disease-free survival after this chemotherapy
regimen. Although the toxicity of this regimen was not insigniﬁ-
cant, it was tolerable considering that the severe toxicity observed
was in general reversible and manageable. These results, added to
the other recent studies that included docetaxel in their treatment
regimens, indicate the interest in this drug in the treatment of
urothelial cancer as an alternative to conventional therapeutic regi-
mens. Further studies aimed at determining more accurately the
potential of docetaxel are warranted together with investigation
into new strategies that will introduce it into three-drug regimens
or in combinations without cisplatin.
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